Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma.
- DOI
- 10.3390/cancers15051568
- Published
- 2023 Mar 2
- Container
- Cancers
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3390/cancers15051568,
title = {Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma.},
author = {Tokunaga T and Tateyama M and Kondo Y and Miuma S and Miyase S and Tanaka K and Narahara S and Inada H and Kurano S and Yoshimaru Y and Nagaoka K and Watanabe T and Setoyama H and Fukubayashi K and Tanaka M and Tanaka Y},
year = {2023},
journal = {Cancers},
doi = {10.3390/cancers15051568},
url = {https://doi.org/10.3390/cancers15051568}
}RIS
TY - JOUR TI - Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma. AU - Tokunaga T AU - Tateyama M AU - Kondo Y AU - Miuma S AU - Miyase S AU - Tanaka K AU - Narahara S AU - Inada H AU - Kurano S AU - Yoshimaru Y AU - Nagaoka K AU - Watanabe T AU - Setoyama H AU - Fukubayashi K AU - Tanaka M AU - Tanaka Y PY - 2023 JO - Cancers DO - 10.3390/cancers15051568 UR - https://doi.org/10.3390/cancers15051568 ER -
APA
T, T., M, T., Y, K., S, M., S, M., K, T., S, N., H, I., S, K., Y, Y., K, N., T, W., H, S., K, F., M, T., & Y, T. (2023). Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma.. Cancers. https://doi.org/10.3390/cancers15051568
Source records
- pubmed · retrieved 2026-09-27T11:02:03.906Z